Síndrome combinado de fibrosis pulmonar y enfisema: albores del tratamiento antifibrótico en el Paraguay

Domingo Pérez-Bejarano

doi:10.18004/mem.iics/1812-9528/2022.020.03.148

Authors

Domingo Pérez-Bejarano Hospital General de Luque, Servicio de Neumología, Área Consultorio Externo. Luque, Paraguay https://orcid.org/0000-0002-9842-4789

DOI:

https://doi.org/10.18004/mem.iics/1812-9528/2022.020.03.148

Keywords:

Combinación de fibrosis pulmonar y enfisema, enfisema pulmonar, fibrosis pulmonar, tabaquismo, hipertensión pulmonar

Abstract

La concomitancia de fibrosis pulmonar en regiones inferiores del pulmón y enfisema en lóbulos superiores caracterizan a una entidad poco frecuente denominada síndrome combinado de fibrosis pulmonar y enfisema, que usualmente se asocia a alta carga de tabaquismo, aunque se describen otras asociaciones y que conlleva un pronóstico sombrío. La hipertensión pulmonar, el cáncer de pulmón y la exacerbación aguda son complicaciones posibles. En el contexto de un enfoque multidisciplinar de manejo de tres casos, relatamos el curso del tratamiento con pirfenidona.

Downloads

Download data is not yet available.

References

Dawod YT, Cook NE, Graham W, Madhani-Lovely F, Thao C. Smoking associated interstitial lung disease: update and review. Expert Review of Respiratory Medicine 2020, 14(8): 825-34. doi: https://doi.org/10.1080/17476348.2020.1766971

Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson A, et al. ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013 Sep 15; 188(6):733-48. doi: https://doi.org/10.1164/rccm.201308-1483ST .

Raghu G, Selman M. Nintedanib and Pirfenidone: New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions. Am J Respir Crit Care Med 2015; 191 (3): 252-254. doi: https://doi.org/10.1164/rccm.201411-2044ED .

Raghu G, Remy-Jardin M, Richeldi L, Thompson C, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022; 205 (9); e15-e47. doi: https://doi.org/10.1164/rccm.202202-0399ST

Auerbach O, Garfinkel L, Hammond EC. Relation of smoking and age to findings in lung parenchyma: a microscopic study. Chest. Jan 1974; 65(1):29-35. doi: https://doi.org/10.1378/chest.65.1.29 .

Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosingalveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med. 1990; 84(5):365-9.doi: https://doi.org/10.1016/s0954-6111(08)80070-4 .

Cottin V, Nunes H, Brillet P, Delaval P, Devouassux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005; 6: 586-93. doi: https://doi.org/10.1183/09031936.05.00021005

Margaritopoulos GA, Harari S, Caminati A, Antoniou KA. Smoking-related idiopathic interstitial pneumonia: a review. Respirology 2016; 21, 57-64. doi: https://doi.org/10.1111/resp.12576 .

Cottin V, Nunes H, Mouthon L, Gamondes D, Lazor R, Hachulla E, et al. Combined Pulmonary Fibrosis and Emphysema in Connective Tissue Diseases. Arthritis & Rheumatism 2011; 63 (1): 295-304. doi: https://doi.org/10.1002/art.30077.

Konoa M, Nakamurab Y, Oyama Y, Saito G, Koyanagi Y, Miyashita K, et al. IgG4-related disease presenting with combined pulmonary fibrosis and emphysema. (CPFE). Resp Med Case Reports 2018; 25: 257-60. doi: https://doi.org/10.1016/j.rmcr.2018.09.017

Karkhanis V, Joshi J. Combined pulmonary fibrosis and emphysema in a Tyre Industry Worker. Lung India 2012; 29(3): 273-6. doi: https://doi.org/10.4103/0970-2113.99116

Jankowich MD, Rounds IS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 2012; 141: 222-231. doi: https://doi.org/10.1378/chest.11-1062

Champtiaux N, Cottin V, Chassagnon G, Chaigne B, Valeire D, Nunes H, et al.; Grouped' Etudes et de Recherche sur les Maladies "Orphelines"pulmonaires (GERM"O"P). Combined pulmonary fibrosis andemphysema in systemic sclerosis: a syndrome associated with heavymorbidity and mortality. Semin Arthritis Rheum 2019; 49: 98-104. doi: https://doi.org/10.1016/j.semarthrit.2018.10.011

Papaioannou A, Kostikas K, Manali E, Papadaki G, Roussou G, Kolilekas L, et al. Combined pulmonary fibrosis and emphysema: The many aspects of a cohabitation contract. Respiratory Medicine 2016; 117: 14-26. doi: https://doi.org/10.1016/j.rmed.2016.05.005

Cosgrove GP, Bianchi P, Canese S, Lederer DJ. Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulmonary Medicine (2018) 18: 9. doi https://doi.org/10.1186/s12890-017-0560-x

Cano-Jiménez E, Vázquez-Rodríguez T, Martin-Robles I, Castillo-Villegas D, Garcia JJ, Bollo de ME, et al. Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis. Scientific Reports 2021 11:9184. https://doi.org/10.1038/s41598-021-88734-2

Inomata M, Ikushima S, Awano N, Kondoh K, Satake K, Masuo M, et al. An autopsy study of combined pulmonary fibrosis and emphysema: correlations among clinical, radiological, and pathological features. BMC Pulm Med 2014; 14: 104. doi: https://doi.org/10.1186/1471-2466-14-104 .

Kinoshita Y, Watanabe K, Ishii H, Kushima H, Fujita M, Nabeshima K, et al. Distribution of emphysema and fibrosis in idiopathic pulmonary fibrosiswith coexisting emphysema. Histopathology 2019; 74: 1103-08. https://doi.org/10.1111/his.13831

Ciftci F, Gulpinar B, Atasoy C, Kayacan O, Saryal S. Combined pulmonary fibrosis and emphysema: how does cohabitation affect respiratory functions? Adv Med Sci 2019; 64: 285-91. doi: https://doi.org/10.1016/j.advms.2019.03.005

Cottin V, Selman M, Inoue Y, Wong A, Corte T, Flaherty K, et al. Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. Am J Respir Crit Care Med 2022; 206 (4): e7-e41. doi: https://doi.org/10.1164/rccm.202206-1041ST

Hage R, Gautschi F, Steinack C, Schuurmans MM. Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management. Int J Chron Obstruct Pulmon Dis. 2021; 28 (16):167-77. doi: https://doi.org/10.2147/COPD.S286360

Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al.; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-9. doi: https://doi.org/10.1016/S0140-6736(11)60405-4 .

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-82. doi: https://doi.oEg/10.1056/NEJMoa1402584 .